Teva Canada Limited v. Janssen Inc., 2023 FCA 68
| Jurisdiction | Federal Jurisdiction (Canada) |
| Court | Court of Appeal (Canada) |
| Citation | 2023 FCA 68 |
| Date | 23 March 2023 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
14 practice notes
-
Takeda Canada Inc. v. Apotex Inc., 2024 FC 106
...in all instances, as infringement can be established even if other non-infringing circumstances exist (Teva Canada Limited v Janssen Inc, 2023 FCA 68 at para 76-79; aff’g Janssen Inc v Teva Canada Ltd, 2020 FC 593 at para 272), I do not find this explanation compelling here. There is......
-
Janssen Inc. v. Apotex Inc., 2023 FCA 253
...as proposed in this appeal in a separate trial involving the 335 Patent and Janssen, against Teva: Teva Canada Limited v. Janssen Inc., 2023 FCA 68, 2023 A.C.W.S. 3380 , aff’g 2020 FC 593 , 321 A.C.W.S. (3d) 539 . Moreover, this Court has previously affirmed “distributing&#......
-
Allergan Inc. v. Juno Pharmaceuticals Corp., 2023 FC 1686
...which is the actual course of conduct that culminated in the making of the invention: see, for example Teva Canada Limited v Janssen Inc, 2023 FCA 68 at para 28. Justice Rennie describes this in the following [107] Beyond the enumerated factors, there are contextual factors that should also......
-
Apotex Inc. v. Janssen Inc., 2023 FCA 220
...or as part of a list of scientific references. [14] This passage, which was recently quoted in Teva Canada Limited v. Janssen Inc., 2023 FCA 68 at para. 106, was considered at paragraph 163 of the Federal Court’s reasons in this case. No inducement was found in Novopharm. However, No......
Request a trial to view additional results
7 cases
-
Takeda Canada Inc. v. Apotex Inc., 2024 FC 106
...in all instances, as infringement can be established even if other non-infringing circumstances exist (Teva Canada Limited v Janssen Inc, 2023 FCA 68 at para 76-79; aff’g Janssen Inc v Teva Canada Ltd, 2020 FC 593 at para 272), I do not find this explanation compelling here. There is......
-
Janssen Inc. v. Apotex Inc., 2023 FCA 253
...as proposed in this appeal in a separate trial involving the 335 Patent and Janssen, against Teva: Teva Canada Limited v. Janssen Inc., 2023 FCA 68, 2023 A.C.W.S. 3380 , aff’g 2020 FC 593 , 321 A.C.W.S. (3d) 539 . Moreover, this Court has previously affirmed “distributing&#......
-
Allergan Inc. v. Juno Pharmaceuticals Corp., 2023 FC 1686
...which is the actual course of conduct that culminated in the making of the invention: see, for example Teva Canada Limited v Janssen Inc, 2023 FCA 68 at para 28. Justice Rennie describes this in the following [107] Beyond the enumerated factors, there are contextual factors that should also......
-
Apotex Inc. v. Janssen Inc., 2023 FCA 220
...or as part of a list of scientific references. [14] This passage, which was recently quoted in Teva Canada Limited v. Janssen Inc., 2023 FCA 68 at para. 106, was considered at paragraph 163 of the Federal Court’s reasons in this case. No inducement was found in Novopharm. However, No......
Request a trial to view additional results
7 firm's commentaries
-
2023 Year In Review: Life Sciences In Canada
...would be available to physicians treating pulmonary arterial hypertension. See the full decision here. Teva Canada Limited v. Janssen Inc, 2023 FCA 68: FCA clarified "but-for" element of the test for inducing infringement of pharmaceutical "use" In Teva v Janssen, the Court of Appeal overtu......
-
FCA Confirms Test For Inducing Patent Infringement
...Canada Limited v. Janssen Inc., 2023 FCA 68, the Federal Court of Appeal confirmed that its previous decision in Corlac Inc. v. Weatherford Canada Inc., 2011 FCA 228 did not change the test for patent infringement by inducement. To establish induced infringement, the patentee must prove tha......
-
Canadian Patent Law 2023: A Year In Review
...the inducer knew that this influence would result in the completion of the acts of infringement. In Teva Canada Limited v Janssen Inc, 2023 FCA 68, the Federal Court of Appeal clarified that "but for" causation by the alleged inducer is not required in the second prong of the test. Specific......
-
Leave To Appeal To The Supreme Court Of Canada Filed In Apotex Inc. V. Janssen Inc. (2024 FCA 9)
...the test for inducement, and particularly the second prong of the test, in other two decisions: Teva Canada Limited v Janssen Inc, 2023 FCA 68 and Apotex Inc v Janssen Inc, 2023 FCA 220. This suggests that the Corlac test, and particularly the second prong, may be an area of increasing judi......
Request a trial to view additional results